Search

Your search keyword '"Fujieda Y"' showing total 230 results
Start Over Author "Fujieda Y"
230 results on '"Fujieda Y"'

1. AB0587 EFFECT OF FISH INTAKE ON PATIENTS WITH RHEUMATOID ARTHRITIS USING BIOLOGICS OR JANUS KINASE INHIBITORS: A JOINT RESEARCH IN JAPAN AND SPAIN

Author

Tarumi, M., primary, Amengual, O., additional, Navidad Fuentes, M., additional, Yasuda, M., additional, Kosumi, Y., additional, Takeyama, S., additional, Yoshimura, M., additional, Ninagawa, K., additional, Aso, K., additional, Hisada, R., additional, Kono, M., additional, Fujieda, Y., additional, Kato, M., additional, Cáliz Cáliz, R., additional, and Atsumi, T., additional

Published
2024
Full Text
View/download PDF

2. OC 76.4 Elevation of Antiphospholipid Antibody Titers Following Vaccination with SARS-CoV-2 mRNA in Patients with Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus

Author

Yasuda, M., primary, Fujieda, Y., additional, Sakiyama, K., additional, Tada, M., additional, Moriya, H., additional, Wei, J., additional, Hisada, R., additional, Kono, M., additional, Kato, M., additional, Amengual, O., additional, Yasumoto, A., additional, Morishita, E., additional, Urano, T., additional, and Atsumi, T., additional

Published
2023
Full Text
View/download PDF

3. AB0459 RELATIONSHIP BETWEEN FISH CONSUMPTION AND RESPONSE TO TREATMENT WITH MOLECULAR TARGETED THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS

Author

Tarumi, M., primary, Amengual, O., additional, Navidad Fuentes, M., additional, Yasuda, M., additional, Kosumi, Y., additional, Takeyama, S., additional, Yoshimura, M., additional, Ninagawa, K., additional, Aso, K., additional, Hisada, R., additional, Kono, M., additional, Fujieda, Y., additional, Kato, M., additional, Cáliz Cáliz, R., additional, and Atsumi, T., additional

Published
2023
Full Text
View/download PDF

6. AB0201 INTAKE OF FISH RICH IN n-3 POLYUNSATURATED FATTY ACIDS IS ASSOCIATED WITH GOOD RESPONSE TO TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING TARGETED THERAPIES.

Author

Tarumi, M., primary, Amengual, O., additional, Fujieda, Y., additional, Navidad Fuentes, M., additional, Tsuchida, N., additional, Yasuda, M., additional, Nishino, K., additional, Kosumi, Y., additional, Takeyama, S., additional, Yoshimura, M., additional, Ninagawa, K., additional, Aso, K., additional, Kono, M., additional, Kato, M., additional, Cáliz Cáliz, R., additional, and Atsumi, T., additional

Published
2022
Full Text
View/download PDF

12. Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome : a longitudinal cohort study

Author

Sato, T., Nakamura, H., 1000070790872, Fujieda, Y., Ohnishi, N., Abe, N., Kono, M., Kato, M., Oku, K., Bohgaki, T., Amengual, O., Yasuda, S., 1000020301905, Atsumi, T., Sato, T., Nakamura, H., 1000070790872, Fujieda, Y., Ohnishi, N., Abe, N., Kono, M., Kato, M., Oku, K., Bohgaki, T., Amengual, O., Yasuda, S., 1000020301905, and Atsumi, T.

Abstract

Objective The objective of this study was to clarify the efficacy and safety of factor Xa inhibitors for antiphospholipid syndrome patients in real world utilization. Methods This is a retrospective cohort study comprised of all consecutive patients with antiphospholipid syndrome in our department over a period of 28 years. Patients treated with factor Xa inhibitors were extracted from the cohort. As a control group, patients treated with warfarin were selected from the same cohort with matched age, gender, coexistence of systemic lupus erythematosus, and the presence of antiplatelet therapy, after which we used a propensity score for each of the risk factors as an additional covariate in multivariate Cox proportional hazard regression. The primary endpoint was set as thrombotic and hemorrhagic event-free survival for five years. Results Among 206 patients with antiphospholipid syndrome, 18 had a history of anti-Xa therapy (five rivaroxaban, 12 edoxaban, one apixaban). Fourteen out of 18 patients on anti-Xa therapy had switched to factor Xa inhibitors from warfarin. Event-free survival was significantly shorter during anti-Xa therapy than that during warfarin therapy (hazard ratio: 12.1, 95% confidence interval: 1.73-248, p = 0.01) (Figure 1(a)). Similarly, event-free survival in patients treated with factor Xa inhibitors was significantly shorter compared with controls (hazard ratio: 4.62, 95% confidence interval: 1.54-13.6, p = 0.0075). In the multivariate Cox proportional hazard model, event-free survival in patients with anti-Xa therapy remained significantly shorter (hazard ratio: 11.9, 95% confidence interval: 2.93-56.0, p = 0.0005). Conclusions Factor Xa inhibitors may not be recommended for antiphospholipid syndrome.

Published
2019

26. AB1139 Autoantibody against complement component 1Q subcomponent is associated with the pathogenesis of recurrent pregnancy loss

Author

Ohmura, K, primary, Oku, K, additional, Kitaori, T, additional, Kono, M, additional, Tanimura, S, additional, Sugawara, E, additional, Hisada, R, additional, Nakamura, H, additional, Shimamura, S, additional, Fujieda, Y, additional, Kato, M, additional, Bohgaki, T, additional, Amengual, O, additional, Yasuda, S, additional, Sugiura-Ogasawara, M, additional, and Atsumi, T, additional

Published
2017
Full Text
View/download PDF

27. FRI0364 Usefulness of serum haptoglobin levels as a novel marker for pulmonary arterial hypertension complicated with connective tissue disease

Author

Nakamura, H, primary, Kato, M, additional, Kono, M, additional, Tanimura, S, additional, Hisada, R, additional, Sugawara, E, additional, Ohmura, K, additional, Shimamura, S, additional, Fujieda, Y, additional, Oku, K, additional, Bohgaki, T, additional, Amengual, O, additional, Yasuda, S, additional, and Atsumi, T, additional

Published
2017
Full Text
View/download PDF

28. FRI0295 High risk of idiopathic osteonecrosis in sle patients with high antiphospholipid score and hypertriglyceridemia

Author

Hisada, R, primary, Kato, M, additional, Ohnishi, N, additional, Kono, M, additional, Tanimura, S, additional, Sugawara, E, additional, Nakamura, H, additional, Ohmura, K, additional, Shimamura, S, additional, Fujieda, Y, additional, Oku, K, additional, Bohgaki, T, additional, Amengual, O, additional, Yasuda, S, additional, and Atsumi, T, additional

Published
2017
Full Text
View/download PDF

30. 29 Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis

Author

Ohnishi, N, primary, Kato, M, additional, Ogata, Y, additional, Abe, S, additional, Kono, M, additional, Shibata, Y, additional, Tanimura, S, additional, Hisada, R, additional, Doi, M, additional, Fujieda, Y, additional, Oku, K, additional, Bohgaki, T, additional, Amengual, O, additional, Yasuda, S, additional, and Atsumi, T, additional

Published
2017
Full Text
View/download PDF

31. Role of apolipoprotein B100 and oxidized low-density lipoprotein in the monocyte tissue factor induction mediated by anti-β2 glycoprotein I antibodies

Author

Otomo, K, primary, Amengual, O, additional, Fujieda, Y, additional, Nakagawa, H, additional, Kato, M, additional, Oku, K, additional, Horita, T, additional, Yasuda, S, additional, Matsumoto, M, additional, Nakayama, K I, additional, Hatakeyama, S, additional, Koike, T, additional, and Atsumi, T, additional

Published
2016
Full Text
View/download PDF

34. Long-term outcome in Japanese patients with lupus nephritis

Author

Kono, M, primary, Yasuda, S, additional, Kato, M, additional, Kanetsuka, Y, additional, Kurita, T, additional, Fujieda, Y, additional, Otomo, K, additional, Horita, T, additional, Oba, K, additional, Kondo, M, additional, Mukai, M, additional, Yanai, M, additional, Fukasawa, Y, additional, and Atsumi, T, additional

Published
2014
Full Text
View/download PDF

35. The involvement of CD36 in monocyte activation by antiphospholipid antibodies

Author

Kato, M., 1000020301905, Atsumi, T., Oku, K., Amengual, O., Nakagawa, H., Fujieda, Y., Otomo, K., Horita, T., Yasuda, S., 1000080146795, Koike, T., Kato, M., 1000020301905, Atsumi, T., Oku, K., Amengual, O., Nakagawa, H., Fujieda, Y., Otomo, K., Horita, T., Yasuda, S., 1000080146795, and Koike, T.

Abstract

Background CD36, known as a scavenger receptor, is a transmembrane glycoprotein expressed on monocytes, platelets and endothelial cells, recognizes multiple ligands, including phosphatidylserine, and regulates atherogenesis and thrombosis. The objective of this study is to investigate the possible involvement of CD36 in the pathophysiology of thrombosis in patients with antiphospholipid syndrome (APS). Methods First, rs3765187, a missense mutation linked to CD36 deficiency, was investigated by TaqMan polymerase chain reaction (PCR) genotyping method in 819 Japanese, including 132 patients with APS, 265 with systemic lupus erythematosus (SLE) in the absence of APS, and 422 healthy subjects. Then, the involvement of CD36 in antiphospholipid antibody (aPL)-induced tissue factor (TF) expression was examined using CD36-null mice or anti-CD36. Purified IgG from patients with APS and a monoclonal phosphatidylserine-dependent antiprothrombin antibody were used in these experiments. TF expression was tested by real-time PCR and flow cytometry. Results Minor allele carrier of rs3765187 was less frequent in patients with APS (3.8% p=0.032), but not in patients with SLE in the absence of APS (7.9% p=0.32), compared with healthy subjects (10.2%). The aPL-induced TF expression was significantly suppressed on peritoneal macrophages from CD36-null mice compared to wild type and significantly inhibited by anti-CD36 on human monocytes. Conclusions The gene mutation linked to CD36 deficiency was less frequent in patients with APS. The deficient or suppressed CD36 function significantly reduced aPL-induced TF expression invitro. Taken together, in a susceptible background CD36 scavenger receptor function may be involved in the thrombotic pathophysiology in patients with APS.

Published
2013

37. FRI0319 The analysis of risk and protective factors for thrombosis in systemic lupus erythematosus with or without antiphospholipid antibodies

Author

Watanabe, T., primary, Oku, K., additional, Amengual, O., additional, Shimamura, S., additional, Nakagawa, I., additional, Noguchi, A., additional, Kanetsuka, Y., additional, Kono, M., additional, Kurita, T., additional, Fujieda, Y., additional, Bohgaki, T., additional, Yasuda, S., additional, Horita, T., additional, and Atsumi, T., additional

Published
2013
Full Text
View/download PDF

39. THU0231 The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis

Author

Kurita, T., primary, Yasuda, S., additional, Oba, K., additional, Otomo, K., additional, Shida, H., additional, Watanabe, T., additional, Kanetsuka, Y., additional, Kono, M., additional, Odani, T., additional, Fujieda, Y., additional, Kon, Y., additional, Horita, T., additional, Sato, N., additional, and Atsumi, T., additional

Published
2013
Full Text
View/download PDF

43. The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: report of five cases and a literature review

Author

Kato, M, primary, Kataoka, H, additional, Odani, T, additional, Fujieda, Y, additional, Otomo, K, additional, Oku, K, additional, Horita, T, additional, Yasuda, S, additional, Atsumi, T, additional, Ohira, H, additional, Tsujino, I, additional, Nishimura, M, additional, and Koike, T, additional

Published
2011
Full Text
View/download PDF

45. Resistance Exercise Enhances Cognitive Function in Mouse.

Author

Inoue, S., Suijo, K., Ohya, Y., Odagiri, Y., Takamiya, T., Ishibashi, H., Itoh, M., Fujieda, Y., and Shimomitsu, T.

Subjects
ANIMAL experimentation, BIOLOGICAL models, COGNITION, EXERCISE, MICE, MUSCLE strength, RESEARCH funding, WESTERN immunoblotting, DATA analysis software, DESCRIPTIVE statistics
Abstract

Physical exercise has been shown to increase adult neurogenesis in the hippocampus and to enhance synaptic plasticity. It has been demonstrated that these neuroprotective eff ects can be observed following aerobic exercise. However, it remains unknown whether plasticity molecules, such as brain-derived neurotrophic factor (BDNF) and cyclic AMP response element-binding protein (CREB), are expressed in the hippocampus following resistance exercise. We applied voluntary progressive-resistance wheel exercise (RE) for 14 days, and measured BDNF and CREB in the hippocampus. The Morris water maze was also performed to estimate learning and memory. Furthermore, we measured RE eff ects on mammalian target of rapamycin (mTOR) and 70-kDa ribosomal protein S6 kinase (p70S6K) mediating muscle protein synthesis in the soleus. As a result, we found that RE enhanced cognition and elevated BDNF and CREB expressions in the hippocampus. Also, RE activated the mTOR-p70S6K signaling pathway in the soleus. We found that phosphorylated mTOR and p70S6K were signifi cantly positively correlated with BDNF expression. Our results indicated that resistance exercise drove the protein synthesis signaling pathway in the soleus and enhanced hippocampal synaptic plasticity-related molecules. These results suggest the benefi cial eff ects of resistance exercise on cognitive function. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

49. Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry.

Author

Kirino Y, Maeda A, Asano T, Migita K, Hidaka Y, Ida H, Kobayashi D, Oda N, Rokutanda R, Fujieda Y, Atsumi T, Kishida D, Kobayashi H, Shiratsuchi M, Shimizu T, Kawakami A, Tanaka K, Tsuji T, Mishima K, Miyamae T, Hasegawa A, Ikeda K, Watanabe T, Yamaguchi Y, Nishikomori R, Ohara O, and Nakajima H

Abstract

Objective: We aimed to gather real-world clinical evidence of detailed disease activity, treatments, remission rates, and adverse events (AEs) associated with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome in a prospective study., Methods: Patients in Japan suspected of having VEXAS syndrome were enrolled in a registry study. A novel disease activity measure (VEXASCAF) assessing 11 symptoms associated with VEXAS syndrome was evaluated at enrolment and after 3 months. AEs, survival, CRP levels, and treatments were also recorded at enrolment and 3 months after enrolment. All exons of UBA1 were sequenced using a next-generation sequencer to determine the variant allele frequencies of pathogenic variants in the peripheral blood of all patients., Results: Of the 55 registered patients, 30 patients were confirmed to have pathogenic variants of UBA1. All patients were male, with a median age of 73.5 years. VEXASCAF and CRP levels decreased significantly at 3 months post-enrolment, but the oral prednisolone dose did not change. Only two patients achieved complete remission according to FRENVEX at 3 months after enrolment. During the observation period of 6 months, 28 AEs were observed, including 3 deaths, 4 malignancies from two cases, 2 thromboses, and 13 infections (including 4 mycobacterial infections). Inflammation of the lung and cervical region (i.e. parotid and submandibular gland swelling, tonsillitis, cervical swelling, and pain) were the most common AEs., Conclusions: Patients with VEXAS syndrome required high-dose glucocorticoids to achieve remission, and complications-such as malignancy, thrombosis, and infection-occurred frequently within a short observation period., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

50. An Association between HTRA1 and TGF-β 2 in the Vitreous Humor of Patients with Chorioretinal Vascular Diseases.

Author

Fukushima Y, Takahashi S, Nakamura M, Inoue T, Fujieda Y, Sato T, Noguchi S, Tsujikawa M, Sakaguchi H, and Nishida K

Abstract

Background : The aim of this paper was to investigate the protein concentrations of high-temperature requirement A 1 (HTRA1) and transforming growth factor-β (TGF-β) in the vitreous humor of patients with chorioretinal vascular diseases. Methods : This study measured protein concentrations of HTRA1, TGF-β1-3, and vascular endothelial growth factor A (hereinafter called VEGF) in the vitreous humor from seven eyes of patients with chorioretinal vascular diseases (age-related macular degeneration, diabetic macular edema, and retinal vein occlusion) and six control eyes (idiopathic epiretinal membrane and macular hole). We analyzed the mutual relationship among the protein levels. Results : The protein levels of HTRA1 and VEGF were significantly increased in the chorioretinal vascular disease group compared with the control group (1.57 ± 0.79 ×10-9 mol/mL vs. 0.68 ± 0.79 ×10-9 mol/mL, p = 0.039; 3447.00 ± 3423.47 pg/mL vs. 35.33 ± 79.01 pg/mL, p = 0.046, respectively). TGF-β2 levels were not significantly different between groups (2222.71 ± 1151.25 pg/mL for the chorioretinal vascular disease group vs. 1918.83 ± 744.01 pg/mL for the control group, p = 0.62). The concentration of HTRA1 was strongly associated with TGF-β2 levels in the vitreous humor, independent of VEGF (r = 0.80, p = 0.0010). Conclusions : We revealed that vitreous HTRA1 was increased in patients with chorioretinal vascular diseases and strongly correlated with TGF-β2.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results